On April 3, 2019 Nerviano Medical Sciences reported two posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in, Atlanta, Georgia, USA regarding preclinical efficacy and safety of NMS-P088, a potent FLT3, KIT and CSF-1R inhibitor with in vitro and in vivo activity also in presence of the gatekeeper mutation, and about the Identification and characterization of ATP-mimetic choline kinase inhibitors (Press release, Nerviano Medical Sciences, APR 3, 2019, View Source [SID1234535098]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the event NMS researchers describes new data regarding NMS-P088 that is a potent and selective FLT3, KIT and CSF-1R inhibitor with in vitro and in vivo activity also in presence of the gatekeeper mutation. Based on NMS-P088 original kinase targets profile, including FLT3 and KIT gatekeeper resistance mutations as well as CSF1R, preclinical efficacy and safety, a Phase I/II clinical trial was started to potentially address unmet medical needs in AML and CMM.
The second presentation regards identification and characterization of ATP-mimetic choline kinase inhibitors. The chemical expansion of ATP-mimetic quinazoline class allowed identification of potent compounds, both in biochemical and in cellular assay, with selectivity against ChoKß and a panel of 60 tyrosine and serine/threonine kinases. Preliminary genomic analysis identified genes differentially expressed in sensitive versus resistant cell lines. Further studies are ongoing to confirm these genes as predictive biomarkers of sensitivity to compounds and to identify other sensitive cancer cell lines. A structure-based drug design optimization program is ongoing with the aim of further improving biological and ADME properties.
Both NMS-P088 and the new choline kinase inhibitors are the results of the Kinase platform in Nerviano Medical Sciences. It represents an integrated system of know-how, technologies and intellectual property developed over the years by the Campus and based on protein kinases as molecular targets. The use of this platform allows the Nerviano research Campus a conspicuous synergy in the efficient development of innovative anticancer drugs.
Presentation title: NMS-P088, a novel FLT3, KIT and CSF1R inhibitor, is a promising clinical candidate for AML and CMML treatment. Marina Ciomei et Al.
Meeting: American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting March 29 – Apr 3, 2019, Atlanta, Georgia, USA (Abs. 1324)
Presentation title: Identification and characterization of ATP-mimetic choline kinase inhibitors. Paola Gnocchi et al
Meeting: American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting March 29 – Apr 3, 2019, Atlanta, Georgia, USA (Abs. 4790)